Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Oncology

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See All Products

Products

See All Products
Resources
Contact
Logout

Boehringer Ingelheim

Glyxambi
Prescribing information
Voice of CRM
Heart Failure Got Treatment
Champs Opens in new tab
Prof Merlin Thomas CKD Video Series
Prof Christoph Wanner’s take on EMPA-KIDNEY
Videos
Let's Talk

JARDIANCE^® provides triple protection in your patients with CRM conditions:

Expert's Opinion on Screening- PCP

20/08/2024 | Author: Boehringer Ingelheim

Document ID: PC-MY-103823

Voice of CRM

PEKP||Expert Opinion on RAASi dose optimization before addition of SGLT2i (Brendon Neuen)

PEKP||Expert's opinion video on synergistic relationship between RAASi and SGLT2i?

PEKP||Expert's Opinion on benefits of starting A1 and A2 patients, regardless of RAASI use at baseline with empagliflozin? (Brendon Neuen)

PEKP||Expert's Opinion on role of screening for HCPS in general (Brendon Neuen)

PEKP||Expert's opinion on starting SGLT2i in lower eGFr/eGFR dip (Brendon Neuen)

PEKP||Expert's Opinion on How is eGFR slope a viable surrogate endpoint for kidney disease progression in clinical trials? (Brendon Neuen)

PEKP||Expert's Opinion on Screening- PCP

RELATED CONTENT

PC-MY-103829-thumbnail-image

1:31

PEKP||Expert Opinion on RAASi dose optimization before addition of SGLT2i (Brendon Neuen)

Watch now Opens in new tab

PC-MY-103828-thumbnail-image

1:12

PEKP||Expert's opinion video on synergistic relationship between RAASi and SGLT2i?

Watch now Opens in new tab

PC-MY-103827-thumbnail-image

1:25

PEKP||Expert's Opinion on benefits of starting A1 and A2 patients, regardless of RAASI use at baseline with empagliflozin? (BrendonNeuen)

Watch now Opens in new tab

PC-MY-103826-thumbnail-image

1:06

PEKP||Expert's Opinion on role of screening for HCPS in general (Brendon Neuen)

Watch now Opens in new tab

PC-MY-103825-thumbnail-image

1:09

PEKP||Expert's opinion on starting SGLT2i in lower eGFr/eGFR dip (Brendon Neuen)

Watch now Opens in new tab

PC-MY-103824-thumbnail-image

1:16

PEKP||Expert's Opinion on How is eGFR slope a viable surrogate endpoint for kidney disease progression in clinical trials? (Brendon Neuen)

Watch now Opens in new tab

Home
Metabolic
Empagliflozin
Voice of CRM
PEKP||Expert's Opinion on Screening- PCP

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Malaysia. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.

Copyright © 2025 Boehringer Ingelheim (Malaysia) Sdn Bhd.
All rights reserved. Use of this site is subject to the Terms of Use and Privacy Statement.